The Pharmacologic Treatment of Anxiety and Depression in African Americans: Considerations for the General Practitioner

Archives of Family Medicine

Volumn 6, Issue 4, 1997, Pages 371-375

  Strickland, Tony L ^a,b,c   Stein, Richard ^a   Lin, Keh Ming ^c   Risby, Emile ^d   Fong, Ronald ^a  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY; BLOOD; DEPRESSION; ETHNOLOGY; GENETICS; HUMAN; NEGRO; REVIEW;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY; DEPRESSION; HUMANS;

EID: 0031181441     PISSN: 10633987     EISSN: None     Source Type: Journal    
DOI: 10.1001/archfami.6.4.371     Document Type: Article

References (43)

1. Marzuk MR. Progress in psychiatry. N Engl J Med. 1993;329:552-560.
2. Simon GE. Psychiatric disorder and functional symptoms as predictors of health care use. Psychiatr Med. 1992;10:49-50.
3. Narrow WE, Regier DA, Rae DS, Mandershceid RW, Locke BZ. Use of services by persons with mental and addictive disorders. Arch Gen Psychiatry. 1993;50:95-107.
4. Walley EJ, Beebe DK, Clark JL. Management of common anxiety disorders. Am Fam Physician. 1994;50:1745-1753.
5. The Depression Guideline Panel of the Agency for Health Care Policy and Research. Synopsis of the clinical practice guidelines for diagnosis and treatment of depression in primary care. Arch Fam Med. 1994;3:85-92.
6. Lin KM, Poland R. Ethnic differences in the response to psychotropic drugs. In: Friedman S, ed. Anxiety Disorders in African Americans. New York, NY: Springer Publishing Co Inc; 1994:203-204.
7. Schulberg HC. Mental disorders in the primary care setting: research priorities for the 1990's. Gen Hosp Psychiatry. 1991;13:156-164.
8. Schulberg HC, Coulehan JL, Block MR, et al. Clinical trials of primary care treatment for major depression: issues in design, recruitment and treatment. Int J Psychiatry Med. 1993;23:29-42.
9. Flaherty JA, Meagher R. Measuring racial bias in inpatient treatment. Am J Psychiatry. 1980;127: 679-682.
10. Lin KM, Poland RE, Chien CP. Ethnicity and psychopharmacology: recent findings and future research directions. In: Sorel E, ed. Family, Culture and Psychobiology. New York, NY: Legas; 1990: 113-131.
11. Strickland TL, Ranganath V, Lin K-M, Poland RE, Mendoza R, Smith MW. Psychopharmacologic considerations in the treatment of black American populations. Psychopharmacol Bull. 1991; 27:441-448.
12. Strickland TL, Lin, K-M, Fu P, Anderson D, Zheng Y. Comparison of lithium ratio between African-American and Caucasian bipolar patients. Soc Biol Psychiatry. 1995;37:325-330.
13. Wood AJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet. 1991;20:1-24.
14. Kalow W, Goedde HW, Agarwal DP, eds. Ethnic Differences in Reactions to Drugs and Xenobiotics. Proceedings of a meeting held in Titisee, Black Forest, Federal Republic of Germany, October 1985. New York, NY: Alan R Liss Inc; 1986.
15. Kalow W. Ethnic differences in drug metabolism. Clin Pharmacokinet. 1982;7:373-400.
16. Lin KM, Poland RE, Lesser IM. Ethnicity and psychopharmacology. Cult Med Psychiatry. 1986;10: 151-165.
17. Adembimpe VR. Psychopharmacological norms in blacks and whites. Am J Psychiatry. 1980;137: 870-871.
18. Adembimpe VR. Overview: white norms and psychiatric diagnosis of black patients. Am J Psychiatry. 1981;138:279-285.
19. Rudorfer MV. Pharmacokinetics of psychotropic drugs in special populations. J Clin Psychiatry. 1993;54(suppl):50-56.
20. Meyer UA, Zanger UM, Grant D, Blim M. Genetic polymorphism of drug metabolism. Adv Drug Res. 1990;19:197-241.
21. Pollock BG. Recent developments in drug metabolism of relevance to psychiatrists. Harvard Rev Psychiatry. 1994;2:204-213.
22. Kalow W. Pharmacogenetics of Drug Metabolism. New York, NY: Pergamon Press Inc; 1992.
23. Tyndale RF, Kalow W, Inaba T. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Br J Clin Pharmacol. 1991;31: 655-660.
24. Kalow W. Pharmacogenetics: its biologic roots and the medical challenge. Clin Pharmacol Ther. 1993; 54:235-241.
25. Goldstein JA, Faletto MB Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans, Biochemlstry. 1994;33:1743-1752.
26. Kalow W. Interethnic variation of drug metabolism. Trends Pharmacol Sci. 1991;12:102-107.
27. Raskin A, Thomas H, Crook MA. Antidepressants in black and white inpatients. Arch Gen Psychiatry. 1975;32:643-649.
28. Overall JE, Hollister LE, Kimball I Jr. A pilot study of racial differences in erythrocyte lithium transport. Am J Psychiatry. 1980;137:120-121.
29. Henry BW, Overall JE, Markette J. Comparison of major drug therapies for alleviation of anxiety and depression. Dis Nerv Syst. 1971;32:655-667.
30. Zeigler VE, Clayton PJ, Biggs JT. A comparison study of amitriptyline and nortriptyline with plasma levels. Arch Gen Psychiatry. 1977;34: 607-612.
31. Livingston RL, Zucker DK, Isenberg K, Wetzel RD. Tricyclic antidepressants and delirium. J Clin Psychiatry. 1983;44:173-176.
32. Rudorfer MV, Robins E. Amitriptyline overdose: clinical effects on tricyclic antidepressant plasma levels. J Clin Psychiatry. 1982;43:457-460.
33. Kilonzo GP, Kaaya SF, Rweikiza JK, Kassam M, Moshi G. Determination of appropriate clomipramine dosage among depressed African outpatients in Dar es Salaam, Tanzania. Cent Afr J Med. 1994;40:178-182.
34. Preskorn S. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Int Clin Psychopharmacol. 1994;9(suppl 3):13-19.
35. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol. 1994;34:262-265.
36. Preskorn SH. The pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry. 1993;54(suppl):5-18.
37. Lasher TA, Fleishaker JC, Steenwyck RC, Antal EJ. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology (Berl). 1991; 104:323-327.
38. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther. 1992;52:479-486.
39. Hollister LE. Antidepressant agents. In: Katzung BG, ed. Basic & Clinical Pharmacology. 6th ed. East Norwalk, Conn: Appleton & Lange; 1995:448-459.
40. Henry BW, Overall, JE Markette J. Comparison of major drug therapies for alleviation of anxiety and depression. Dis Nerv Syst. 1971;23:655-667.
41. Olfson M, Pincus HA. Use of benzodiazepines in the community. Arch Intern Med. 1994;154:1235-1240.
42. Swartz M, Landerman R, George LK, Melville ML, Blazer D, Smith K. Benzodiazepine anti-anxiety agents: relevance and correlates of use in a southern community. Am J Public Health. 1991;81:592-596.
43. Zisselman MH, Rovner BW, Kelly KG, Woods C. Benzodiazepine utilization in a university hospital. Am J Med Qual. 1994;9:138-141.